Donald McDonnell, PhD, associate director for Translational Research, DCI, receives prestigious St. Patrick's Day Irish science medal for contributions to academia and industry.
“Each time there are new diagnostic tools and there are new treatments. I've been following the wave for 22 years now." — prostate cancer survivor Michael Johnstone.
Duke Cancer Institute researchers Jiaoti Huang, MD, PhD, Brant Inman, MD, and Qing Cheng, PhD, have identified a molecular signature that can spot aggressive cells.
Astellas Pharma Inc. announced on May 4 that the European Commission has approved enzalutamide for adult men with metastatic hormone-sensitive prostate cancer.
This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.
Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.
Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.
DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.
DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.
ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.
Andrew Armstrong, MD, found that treatment with enzalutamide and ADT significantly reduced the risk of metastasis or death over time in men with mHSPC.
While there have been many successes with newer chemotherapies, targeted therapies, and immunotherapies, many cancer types in the human population don...
When Robert “Bob” List, 73, a retired colonel with the U.S. Marine Corps, was diagnosed with stage 2 prostate cancer, he immediately began to research the “enemy” threat.
Black men are underrepresented in clinical trials for prostate cancer, despite an almost two-fold greater incidence and mortality of disease in black versus white populations.
Five years after surgery to treat prostate cancer, Steele Dewey of Charlotte, North Carolina was told that the cancer had spread. He chose Dan George, MD, at Duke.
When his dad passed away from cancer, Myles Owens IV launched a clothing line in his memory. Part of the proceeds benefit Duke Cancer Institute research.
Duke Cancer Institute (DCI) recently announced the formation of a new center, Duke Prostate and Urologic Cancer Center, a center of excellence support...
Shared decision-making in health care has been touted as a way to include patient preferences in treatment plans, better balance treatment risks and b...
In celebration of dads, Pedro Williams, only the hippest barber shop in Durham, is teaming up with Give 1 For Dad and offering FREE cuts and shaves on...
Get in the game — know your scores. Duke Cancer Institute's Office of Health Equity (OHE) and its partner Lincoln Community Health Center will offer F...
Black men face an unfortunate paradox when it comes to prostate cancer. They are the group hit hardest by this common disease, yet they are less likel...
William Shakespeare said it best when he penned “All the world’s a stage.” No doubt, no one knows this better than Johnny Alston, a 41-year theater pr...
Get in the game — know your scores. Duke Cancer Institute and its partner, Lincoln Community Health Center, will offer FREE prostate cancer screenings...
Duke Cancer Institute’s Gita Suneja, MD, MSHP, has received a five-year National Cancer Institute Mentored Clinical Scientist Research Career Developm...
African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study...
According to the American Cancer Society, one in two men and one in three women in the United States will be affected by cancer in their lifetime. It ...
More than 20 MoDukes, supporters of the Movember Foundation and members of Team Duke Cancer Institute, signed on to shave-down on Wednesday, Nov. 1, a...